BioAtla
phase study design with | BioAtla
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
18 of 43
Similar slides by BioAtla
See diffirences between slides (animation)
Investor Presentation
May 2023
phase study design with | BioAtla
Investor Presentation
November 2022
phase study design with in refractory patients | BioAtla
Investor Presentation
November 2022
phase study design with | BioAtla
Investor Presentation
August 2022
phase study design with in refractory patients | BioAtla
Related slides by other companies
Anebulo Pharmaceuticals
Investor Day
September 2022
phase part adaptive study design | Anebulo Pharmaceuticals
ATAI
Investor Presentation
November 2022
subjects parallel arms of subjects data expected by year end placebo and intravenous primary depression rating scale at hours clinician administered dissociative states scale cadss key safety tolerability running across multiple sites in and the preparations to initiate the phase comparative study to bridge from to a subcutaneous formulation continue phase study will be completed this year randomized establish human proof of concept | ATAI
Tonix Pharmaceuticals
Investor Presentation
October 2022
phase resilient study design | Tonix Pharmaceuticals
MindMed
Investor Presentation
December 2024
phase trial of utilized standard gad design and and was aligned with draft guidance for drug class class | MindMed
Other recent decks by BioAtla
See all presentations (8 decks)
Investor Presentation
January 2024
Investor Presentation
May 2023
Investor Presentation
November 2022
Investor Presentation
August 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights